Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

Rather than requiring a new trial, the FDA extended evidence from carcinoma in situ to high-grade papillary-only disease, a new approach for this setting.

Pharmacists can address patient fears about fentanyl by distinguishing illicit from prescribed opioids and promoting safe, empathetic, evidence-based opioid use.

Nationwide Danish data presented at EASD 2026 link a widening cancer gap in type 2 diabetes largely to obesity-related cancers.

Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.

Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.

In an era of rapidly evolving technology, we remain in a people-powered world.

Victoria P. Werth, MD, discusses how litifilimab’s 52-week AMETHYST findings inform treatment expectations and timely reassessment of persistent cutaneous lupus symptoms.

In an interview with Pharmacy Times, Victoria P. Werth, MD, professor of dermatology at the University of Pennsylvania and chief of dermatology at the Philadelphia VA Medical Center, discusses why meaningful improvement extends beyond skin clearance and how response timing affects patients with difficult-to-control disease.